Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial.

Favrais G, Ursino M, Mouchel C, Boivin E, Jullien V, Zohar S, Saliba E.

BMJ Open. 2019 Jan 24;9(1):e022739. doi: 10.1136/bmjopen-2018-022739.

2.

Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data.

Rodrigues C, Chiron C, Ounissi M, Dulac O, Gaillard S, Nabbout R, Jullien V.

Epilepsy Res. 2019 Feb;150:38-45. doi: 10.1016/j.eplepsyres.2019.01.002. Epub 2019 Jan 7.

PMID:
30639958
3.

Successful Treatment of Saksenaea sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads.

Parize P, Mamez AC, Garcia-Hermoso D, Dumaine V, Poirée S, Kauffmann-Lacroix C, Jullien V, Lortholary O, Lanternier F.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01006-18. doi: 10.1128/AAC.01006-18. Print 2019 Jan.

PMID:
30373790
4.

Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data.

Ounissi M, Rodrigues C, Bienayme H, Duhamel P, Pons G, Dulac O, Nabbout R, Chiron C, Jullien V.

J Clin Pharmacol. 2019 Feb;59(2):177-188. doi: 10.1002/jcph.1309. Epub 2018 Sep 7.

PMID:
30192381
5.

[Use of pocket-sized ultrasound in internal medicine (hospitalist) practice: Feedback and perspectives].

Michon A, Jammal S, Passeron A, De Luna G, Bomahou C, Jullien V, Pouchot J, Arlet JB, Ranque B.

Rev Med Interne. 2019 Apr;40(4):220-225. doi: 10.1016/j.revmed.2018.07.003. Epub 2018 Aug 2. French.

PMID:
30078545
6.

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P; WWARN Amodiaquine PK Study Group .

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e02193-17. doi: 10.1128/AAC.02193-17. Print 2018 Oct.

7.

Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?

Danion F, Jullien V, Rouzaud C, Abdel Fattah M, Lapusan S, Guéry R, Bigé N, Morgand M, Pallet N, Lanternier F, Lortholary O.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00705-18. doi: 10.1128/AAC.00705-18. Print 2018 Sep.

8.

Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis.

Pilmis B, Garcia-Hermoso D, Alanio A, Catherinot E, Scemla A, Jullien V, Bretagne S, Lortholary O.

Am J Transplant. 2018 Sep;18(9):2352-2355. doi: 10.1111/ajt.14940. Epub 2018 Jul 12.

PMID:
29790292
9.

A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Rodrigues C, Chhun S, Chiron C, Dulac O, Rey E, Pons G, Jullien V.

Eur J Clin Pharmacol. 2018 Jun;74(6):793-803. doi: 10.1007/s00228-018-2444-2. Epub 2018 Mar 21.

PMID:
29564480
10.

Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.

Launay M, Roux A, Beaumont L, Douvry B, Lecuyer L, Douez E, Picard C, Grenet D, Jullien V, Boussaud V, Guillemain R, Billaud EM.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02061-17. doi: 10.1128/AAC.02061-17. Print 2018 Mar.

11.

Leflunomide for BKvirus: Report of Seven Kidney-Transplanted Children.

Launay M, Baudouin V, Guillemain R, Maisin A, Flodrops H, Douez E, Mavoungou S, Jullien V, Billaud EM.

Int J Organ Transplant Med. 2018;9(4):178-183. Epub 2018 Nov 1.

12.

Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Pilmis B, Jullien V, Tabah A, Zahar JR, Brun-Buisson C.

Ann Intensive Care. 2017 Nov 10;7(1):113. doi: 10.1186/s13613-017-0334-x. Review.

13.

Determination of the R(-) and S(+)-enantiomers of vigabatrin in human plasma by ultra-high-performance liquid chromatography and tandem mass-spectrometry.

Duhamel P, Ounissi M, Le Saux T, Bienayme H, Chiron C, Jullien V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 1;1070:31-36. doi: 10.1016/j.jchromb.2017.10.037. Epub 2017 Oct 20.

PMID:
29107733
14.

In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Raffetin A, Courbin V, Jullien V, Dannaoui E.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01382-17. doi: 10.1128/AAC.01382-17. Print 2018 Jan.

15.

Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.

Peigné S, Chhun S, Tod M, Rey E, Rodrigues C, Chiron C, Pons G, Jullien V.

Clin Pharmacokinet. 2018 Jun;57(6):739-748. doi: 10.1007/s40262-017-0592-7.

PMID:
28819726
16.

Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G, Jullien V.

Br J Clin Pharmacol. 2017 Dec;83(12):2695-2708. doi: 10.1111/bcp.13392. Epub 2017 Sep 20.

17.

Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere?

Hamdidouche I, Jullien V, Laurent S, Azizi M.

Hypertension. 2017 Aug;70(2):257-258. doi: 10.1161/HYPERTENSIONAHA.117.09739. Epub 2017 Jun 26. No abstract available.

PMID:
28652471
18.

Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients.

Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S.

J Hypertens. 2017 Sep;35(9):1891-1898. doi: 10.1097/HJH.0000000000001402.

PMID:
28505066
19.

Drug adherence in hypertension: from methodological issues to cardiovascular outcomes.

Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S.

J Hypertens. 2017 Jun;35(6):1133-1144. doi: 10.1097/HJH.0000000000001299. Review.

PMID:
28306634
20.

An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples.

Toussaint B, Lanternier F, Woloch C, Fournier D, Launay M, Billaud E, Dannaoui E, Lortholary O, Jullien V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:26-33. doi: 10.1016/j.jchromb.2017.01.036. Epub 2017 Jan 23.

PMID:
28131025
21.

Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING.

Spire B, Nait-Ighil L, Pugliese P, Poizot-Martin I, Jullien V, Marcelin AG, Billaud E.

HIV Clin Trials. 2017 Jan;18(1):1-16. doi: 10.1080/15284336.2016.1251030.

PMID:
28125951
22.

Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices.

Vassallo M, Genillier PL, Dunais B, Kaphan R, Saudes L, Duval Y, Rolland F, Jullien V, Weiss N, Blanchouin E, Boscagli A, Perrin C, Montagne N.

J Chemother. 2017 Aug;29(4):232-237. doi: 10.1080/1120009X.2017.1282335. Epub 2017 Jan 25.

PMID:
28120698
23.

Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.

Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar JR, Jullien V.

Int J Antimicrob Agents. 2017 Jan;49(1):62-66. doi: 10.1016/j.ijantimicag.2016.09.027. Epub 2016 Nov 15.

PMID:
27876276
24.

Acute reversible pancreatitis induced by posaconazole.

Pilmis B, Coignard-Biehler H, Rouzaud C, Jullien V, Lanternier F, Lortholary O.

J Antimicrob Chemother. 2017 Feb;72(2):628-630. doi: 10.1093/jac/dkw465. Epub 2016 Nov 17. No abstract available.

PMID:
27856723
25.

Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.

Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, Wolff M; EMPIRICUS Trial Group.

JAMA. 2016 Oct 18;316(15):1555-1564. doi: 10.1001/jama.2016.14655.

PMID:
27706483
26.

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.

Petit C, Samson A, Morita S, Ursino M, Guedj J, Jullien V, Comets E, Zohar S.

Stat Methods Med Res. 2018 Jun;27(6):1860-1877. doi: 10.1177/0962280216671348. Epub 2016 Oct 5.

27.

Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.

Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, Timsit JF; EMPIRICUS Trial Study Group.

J Antimicrob Chemother. 2017 Jan;72(1):181-189. Epub 2016 Sep 8.

PMID:
27609051
28.

Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.

Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, Houzé P, Ashley EA, Kiechel JR, Guérin PJ, Le Bras J, Houzé S.

Malar J. 2016 Sep 5;15:452. doi: 10.1186/s12936-016-1503-3.

29.

Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.

Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Girerd X, Michel Halimi J, Zannad F, Ormezzano O, Vaïsse B, Herpin D, Ribstein J, Chamontin B, Mourad JJ, Ferrari E, Plouin PF, Jullien V, Sapoval M, Chatellier G; DENERHTN Investigators.

Circulation. 2016 Sep 20;134(12):847-57. doi: 10.1161/CIRCULATIONAHA.116.022922. Epub 2016 Aug 30.

PMID:
27576780
30.

Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.

de Kerviler E, Maravilla K, Meder JF, Naggara O, Dubourdieu C, Jullien V, Desché P.

Invest Radiol. 2016 Sep;51(9):544-51. doi: 10.1097/RLI.0000000000000276.

PMID:
27504794
31.

Rifabutin: where do we stand in 2016?

Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O.

J Antimicrob Chemother. 2016 Jul;71(7):1759-71. doi: 10.1093/jac/dkw024. Epub 2016 Mar 23. Review.

PMID:
27009031
32.

Aspergillus spp. invasive external otitis: favourable outcome with a medical approach.

Marchionni E, Parize P, Lefevre A, Vironneau P, Bougnoux ME, Poiree S, Coignard-Biehler H, DeWolf SE, Amazzough K, Barchiesi F, Jullien V, Alanio A, Garcia-Hermoso D, Wassef M, Kania R, Lortholary O, Lanternier F.

Clin Microbiol Infect. 2016 May;22(5):434-7. doi: 10.1016/j.cmi.2015.12.027. Epub 2016 Jan 21.

33.

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1481-91. doi: 10.1128/AAC.01125-15.

34.

Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.

Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet-Revillet H, Poirée S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A.

J Antimicrob Chemother. 2016 Feb;71(2):513-20. doi: 10.1093/jac/dkv361. Epub 2015 Nov 12.

PMID:
26565016
35.

A review of potential pharmacogenetic effects on catecholamine responses.

Ounissi M, Benkirane A, Dempsey E, Soares R, Jullien V, Pons G, Chhun S.

Drug Metab Rev. 2015;47(4):558-64. doi: 10.3109/03602532.2015.1102932. Epub 2015 Nov 3. Review.

PMID:
26530497
36.

Bumetanide for neonatal seizures-back from the cotside.

Pressler RM, Boylan GB, Marlow N, de Vries LS, Blennow M, Chiron C, Cross JH, Hallberg B, Hellström-Westas L, Jullien V, Mangum B, Murphy B, Murray D, Pons G, Rennie J, Toet MC, Zohar S; NEMO consortium (NEonatal seizure treatment with Medication Off-patent).

Nat Rev Neurol. 2015 Dec;11(12):724. doi: 10.1038/nrneurol.2015.116. Epub 2015 Nov 3. No abstract available.

PMID:
26526530
37.

[Pruritus, asthenia and paresthesia in a 51-year-old man].

Michon A, Passeron A, Ranque B, Jullien V, Arlet JB, Pouchot J, Morell-Dubois S.

Rev Med Interne. 2015 Dec;36(12):859-61. doi: 10.1016/j.revmed.2015.05.002. Epub 2015 Aug 28. French. No abstract available.

PMID:
26318842
38.

Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures.

Jullien V, Pressler RM, Boylan G, Blennow M, Marlow N, Chiron C, Pons G; NEMO Consortium Neonatal Seizure Treatment With Medication Off-Patent.

J Clin Pharmacol. 2016 Mar;56(3):284-90. doi: 10.1002/jcph.596. Epub 2015 Sep 14.

PMID:
26189501
39.

[Noninvasive ventilation for acute respiratory failure in a pulmonary department].

Perrin C, Rolland F, Berthier F, Duval Y, Jullien V.

Rev Mal Respir. 2015 Nov;32(9):895-902. doi: 10.1016/j.rmr.2015.03.002. Epub 2015 Jun 3. French.

40.

The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WR, Temu EA, Thwing JI, Tjitra E, Tine RC, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I.

BMC Med. 2015 Mar 31;13:66. doi: 10.1186/s12916-015-0301-z.

41.

Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.

Curis E, Pestre V, Jullien V, Eyrolle L, Archambeau D, Morand P, Gatin L, Karoubi M, Pinar N, Dumaine V, Nguyen Van JC, Babinet A, Anract P, Salmon D.

Infection. 2015 Aug;43(4):473-81. doi: 10.1007/s15010-015-0773-y. Epub 2015 Apr 3.

PMID:
25837442
42.

Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.

Pressler RM, Boylan GB, Marlow N, Blennow M, Chiron C, Cross JH, de Vries LS, Hallberg B, Hellström-Westas L, Jullien V, Livingstone V, Mangum B, Murphy B, Murray D, Pons G, Rennie J, Swarte R, Toet MC, Vanhatalo S, Zohar S; NEonatal seizure treatment with Medication Off-patent (NEMO) consortium.

Lancet Neurol. 2015 May;14(5):469-77. doi: 10.1016/S1474-4422(14)70303-5. Epub 2015 Mar 10.

PMID:
25765333
43.

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F.

Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.

44.

Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.

Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, Taylor WR, Kiechel JR.

Malar J. 2014 Dec 16;13:498. doi: 10.1186/1475-2875-13-498.

45.

Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.

Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, Pons G.

Clin Pharmacokinet. 2015 May;54(5):527-36. doi: 10.1007/s40262-014-0223-5.

PMID:
25503589
46.

Antifungal drugs during pregnancy: an updated review.

Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C.

J Antimicrob Chemother. 2015 Jan;70(1):14-22. doi: 10.1093/jac/dku355. Epub 2014 Sep 8. Review.

PMID:
25204341
47.

Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.

Kloprogge F, Jullien V, Piola P, Dhorda M, Muwanga S, Nosten F, Day NP, White NJ, Guerin PJ, Tarning J.

J Antimicrob Chemother. 2014 Nov;69(11):3033-40. doi: 10.1093/jac/dku228. Epub 2014 Jun 25.

48.
49.

Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.

Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, Bille E, Jullien V, Zahar JR.

Antimicrob Agents Chemother. 2014 Aug;58(8):4899-901. doi: 10.1128/AAC.02509-14. Epub 2014 Apr 28.

50.

Reassessment of stiripentol pharmacokinetics in healthy adult volunteers.

Peigné S, Rey E, Le Guern ME, Dulac O, Chiron C, Pons G, Jullien V.

Epilepsy Res. 2014 Jul;108(5):909-16. doi: 10.1016/j.eplepsyres.2014.03.009. Epub 2014 Mar 26.

PMID:
24725808

Supplemental Content

Loading ...
Support Center